$clpt $ngne
I think I might have found the missing link, I was concerned that usually clearpoint is not involved with ICV but check this out
pmc.ncbi.nlm.nih.gov/articles/PMC12…
GS-100 or vehicle administration
i.c.v. administration of GS-100 in wild-type and Ngly1−/− rats was conducted on PND 27–29, as previously described.6
A ClearPoint SmartFlow cannula (ClearPoint Neuro, Solana Beach, CA) was carefully lowered into place, and either GS-100 or vehicle (0.001% Poloxamer 188 in sterile phosphate-buffered saline [PBS]) was infused into the lateral ventricle.
So now we connect Daniel Curry to Grace Science using ICV. NGLY-1 is Grace Science. It’s not likely he creates a program, uses clearpoint for Aadc first, doesn’t use Clearpoint for Rett for ICV and now does Grace Science for clearpoint for ICV. Logically doesn’t really make sense. I think the probability of Neurogene’s rett program being clearpoint just went up.
My last post on this topic referenced this, I didn’t connect the ICV and Grace connection, I connected the Grace connection but I didn’t fully grasp that they are using ICV. My biggest concern has always been that Clearpoint typically isn’t involved in ICV. Which clearly they are on a program directly created from the same guy that did aadc, rett and Ngly
Seems highly unlikely that a program created out of his lab wouldn’t be using Clearpoint in this sequence of events. See bottom 2 paragraphs.
Daniel Curry new disclosure
Daniel Curry: Advisory board (NeuroPace), Consultant (Clearpoint Neuro), PTC Therapeutics) Neurogene and Grace Scientific
Clearpoint works with Neuropace,
He is a consultant for clearpoint
He was a big part in the aadc trial, he did the first commercial surgery in the US for aadc
Grace Science is using our cannula and is doing the delivery as “ICV”
Now that is 4 out of 4, he did the first procedures of Neurogene..
Which gives us a decent probability of being our program, obviously no guarantees but everything else that we know about this program, the probability just went up again that we have a 2nd BTD,
Dr. Curry helped develop the Texas Children’s Intracerebral Gene Therapy Program with investigations into intraputamenal gene therapy for AADC deficiency, as well as investigations into gene therapy for Rett syndrome and NGLY-1 deficiency. Dr. Curry is also Director of the Neuroinfusion Service at Texas Children’s, conducting intracerebral enzyme replacement therapy in Batten’s disease and other neurodegenerative diseases.
“With these exciting advancements in gene delivery and surgical precision, we can not only treat the root cause of diseases in the brain, but hopefully reverse them,” said Dr. Curry. “This will make a life-changing difference for so many patients.”